We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Walgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Walgreens Boots Alliance (WBA - Free Report) closed at $43.55 in the latest trading session, marking a +0.58% move from the prior day. The stock lagged the S&P 500's daily gain of 0.82%. At the same time, the Dow added 1.05%, and the tech-heavy Nasdaq gained 0.59%.
Wall Street will be looking for positivity from WBA as it approaches its next earnings report date. The company is expected to report EPS of $1.19, down 19.05% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $34.23 billion, down 1.03% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.48 per share and revenue of $138.47 billion. These totals would mark changes of -8.51% and +1.17%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for WBA. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.86% lower. WBA is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note WBA's current valuation metrics, including its Forward P/E ratio of 7.9. Its industry sports an average Forward P/E of 9.31, so we one might conclude that WBA is trading at a discount comparatively.
Also, we should mention that WBA has a PEG ratio of 2.01. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Retail - Pharmacies and Drug Stores stocks are, on average, holding a PEG ratio of 1.75 based on yesterday's closing prices.
The Retail - Pharmacies and Drug Stores industry is part of the Retail-Wholesale sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Walgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know
Walgreens Boots Alliance (WBA - Free Report) closed at $43.55 in the latest trading session, marking a +0.58% move from the prior day. The stock lagged the S&P 500's daily gain of 0.82%. At the same time, the Dow added 1.05%, and the tech-heavy Nasdaq gained 0.59%.
Wall Street will be looking for positivity from WBA as it approaches its next earnings report date. The company is expected to report EPS of $1.19, down 19.05% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $34.23 billion, down 1.03% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.48 per share and revenue of $138.47 billion. These totals would mark changes of -8.51% and +1.17%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for WBA. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.86% lower. WBA is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note WBA's current valuation metrics, including its Forward P/E ratio of 7.9. Its industry sports an average Forward P/E of 9.31, so we one might conclude that WBA is trading at a discount comparatively.
Also, we should mention that WBA has a PEG ratio of 2.01. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Retail - Pharmacies and Drug Stores stocks are, on average, holding a PEG ratio of 1.75 based on yesterday's closing prices.
The Retail - Pharmacies and Drug Stores industry is part of the Retail-Wholesale sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.